KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments: 2011-2018

Historic Long-Term Debt Repayments for Vertex Pharmaceuticals (VRTX) over the last 6 years, with Dec 2018 value amounting to $8.1 million.

  • Vertex Pharmaceuticals' Long-Term Debt Repayments rose 76.56% to $8.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $27.9 million, marking a year-over-year increase of 48.58%. This contributed to the annual value of $27.9 million for FY2018, which is 48.58% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Long-Term Debt Repayments of $8.1 million as of Q4 2018, which was up 41.93% from $5.7 million recorded in Q3 2018.
  • Over the past 5 years, Vertex Pharmaceuticals' Long-Term Debt Repayments peaked at $264.1 million during Q3 2014, and registered a low of -$272.9 million during Q4 2014.
  • Its 3-year average for Long-Term Debt Repayments is $5.4 million, with a median of $4.8 million in 2017.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first slumped by 18,845.88% in 2014, then soared by 13,426.80% in 2016.
  • Vertex Pharmaceuticals' Long-Term Debt Repayments (Quarterly) stood at -$272.9 million in 2014, then soared by 107.21% to $19.7 million in 2015, then slumped by 78.31% to $4.3 million in 2016, then rose by 7.97% to $4.6 million in 2017, then spiked by 76.56% to $8.1 million in 2018.
  • Its Long-Term Debt Repayments stands at $8.1 million for Q4 2018, versus $5.7 million for Q3 2018 and $4.9 million for Q2 2018.